These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 12375643)

  • 21. Treatment of CD33 positive refractory acute lymphoblastic leukemia with Mylotarg.
    Cheung KC; Wong LG; Yeung YM
    Leuk Lymphoma; 2008 Mar; 49(3):596-7. PubMed ID: 18297542
    [No Abstract]   [Full Text] [Related]  

  • 22. Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia.
    Laszlo GS; Harrington KH; Gudgeon CJ; Beddoe ME; Fitzgibbon MP; Ries RE; Lamba JK; McIntosh MW; Meshinchi S; Walter RB
    Oncotarget; 2016 Jul; 7(28):43281-43294. PubMed ID: 27248327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Compound Zhebei Granule () combined with chemotherapy on surface markers of leukemia stem cell in patients with acute myeloid leukemia.
    Wang J; Lai ZL; Chen XY; Li DY; Zhang YY; Ma W; Chu YT; Shi FQ; Yang L; Hou L
    Chin J Integr Med; 2016 Jun; 22(6):438-44. PubMed ID: 26666761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial.
    Raza A; Jurcic JG; Roboz GJ; Maris M; Stephenson JJ; Wood BL; Feldman EJ; Galili N; Grove LE; Drachman JG; Sievers EL
    Leuk Lymphoma; 2009 Aug; 50(8):1336-44. PubMed ID: 19557623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.
    Kenderian SS; Ruella M; Shestova O; Klichinsky M; Aikawa V; Morrissette JJ; Scholler J; Song D; Porter DL; Carroll M; June CH; Gill S
    Leukemia; 2015 Aug; 29(8):1637-47. PubMed ID: 25721896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Antibody therapy for acute leukemia].
    Takeshita A
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():408-15. PubMed ID: 17474439
    [No Abstract]   [Full Text] [Related]  

  • 27. CD33 expression on natural killer cells is a potential confounder for residual disease detection in acute myeloid leukemia by flow cytometry.
    Eckel AM; Cherian S; Miller V; Soma L
    Cytometry B Clin Cytom; 2020 Mar; 98(2):174-178. PubMed ID: 31622025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858.
    Eksioglu EA; Chen X; Heider KH; Rueter B; McGraw KL; Basiorka AA; Wei M; Burnette A; Cheng P; Lancet J; Komrokji R; Djeu J; List A; Wei S
    Leukemia; 2017 Oct; 31(10):2172-2180. PubMed ID: 28096534
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monoclonal antibody therapy of APL.
    Maslak PG; Jurcic JG; Scheinberg DA
    Curr Top Microbiol Immunol; 2007; 313():205-19. PubMed ID: 17217045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia.
    Laing AA; Harrison CJ; Gibson BES; Keeshan K
    Exp Hematol; 2017 Oct; 54():40-50. PubMed ID: 28668350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy.
    Willier S; Rothämel P; Hastreiter M; Wilhelm J; Stenger D; Blaeschke F; Rohlfs M; Kaeuferle T; Schmid I; Albert MH; Binder V; Subklewe M; Klein C; Feuchtinger T
    Blood; 2021 Feb; 137(8):1037-1049. PubMed ID: 33094319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Gallazzi M; Ucciero MAM; Faraci DG; Mahmoud AM; Al Essa W; Gaidano G; Mouhssine S; Crisà E
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel CD33 antibodies unravel localization, biology and therapeutic implications of CD33 isoforms.
    Gbadamosi MO; Shastri VM; Hylkema T; Papageorgiou I; Pardo L; Cogle CR; Doty A; Loken MR; Meshinchi S; Lamba JK
    Future Oncol; 2021 Jan; 17(3):263-277. PubMed ID: 33356566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TNFα induces Caspase-3 activity in hematopoietic progenitor cells CD34+, CD33+, and CD41 + of myelodysplastic syndromes.
    Iriani A; Rachman A; Setiabudy RD; Kresno SB; Sudoyo AW; Arief M; Harahap AR; Fatina MK
    BMC Mol Cell Biol; 2023 Nov; 24(1):33. PubMed ID: 37990142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count.
    Sanford D; Garcia-Manero G; Jorgensen J; Konoplev S; Pierce S; Cortes J; Kantarjian H; Ravandi F
    Leuk Lymphoma; 2016 Aug; 57(8):1965-8. PubMed ID: 26726757
    [No Abstract]   [Full Text] [Related]  

  • 36. Flow cytometry in the diagnosis of myelodysplastic syndromes and the value of myeloid nuclear differentiation antigen.
    Bellos F; Kern W
    Cytometry B Clin Cytom; 2017 May; 92(3):200-206. PubMed ID: 26184452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A.
    Stanchina M; Pastore A; Devlin S; Famulare C; Stein E; Taylor J
    J Hematol Oncol; 2019 Aug; 12(1):85. PubMed ID: 31439003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is hepatotoxicity in patients treated with gemtuzumabozogamicin due to specific targeting of hepatocytes?
    Maniecki MB; Hasle H; Bendix K; Møller HJ
    Leuk Res; 2011 Jun; 35(6):e84-6. PubMed ID: 21329979
    [No Abstract]   [Full Text] [Related]  

  • 39. CD33 as a leukocyte-associated marker expressed on human spermatozoa.
    Sereshki N; Rafiee M; Alipour R; Rahimyan K; Wilkinson D
    BMC Res Notes; 2023 Apr; 16(1):57. PubMed ID: 37081561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective killing of leukemia and lymphoma cells ectopically expressing hCGbeta by a conjugate of curcumin with an antibody against hCGbeta subunit.
    Vyas HK; Pal R; Vishwakarma R; Lohiya NK; Talwar GP
    Oncology; 2009; 76(2):101-11. PubMed ID: 19127081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.